178 related articles for article (PubMed ID: 38098228)
1. Superantigen-fused T cell engagers for tumor antigen-mediated robust T cell activation and tumor cell killing.
Zhao WB; Shen Y; Cai GX; Li YM; Liu WH; Wu JC; Xu YC; Chen SQ; Zhou Z
Mol Ther; 2024 Feb; 32(2):490-502. PubMed ID: 38098228
[TBL] [Abstract][Full Text] [Related]
2. Development of T-cell engagers selective for cells co-expressing two antigens.
Dicara DM; Bhakta S; Go MA; Ziai J; Firestein R; Forrest B; Gu C; Leong SR; Lee G; Yu SF; Polson AG; Agard NJ
MAbs; 2022; 14(1):2115213. PubMed ID: 36206404
[TBL] [Abstract][Full Text] [Related]
3. Cancer cell-intrinsic resistance to BiTE therapy is mediated by loss of CD58 costimulation and modulation of the extrinsic apoptotic pathway.
Shen Y; Eng JS; Fajardo F; Liang L; Li C; Collins P; Tedesco D; Nolan-Stevaux O
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296559
[TBL] [Abstract][Full Text] [Related]
4. Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression.
Ding Z; Sun S; Wang X; Yang X; Shi W; Huang X; Xie S; Mo F; Hou X; Liu A; Jiang X; Tang Z; Lu X
J Hematol Oncol; 2023 Nov; 16(1):115. PubMed ID: 38031188
[TBL] [Abstract][Full Text] [Related]
5. Improving the tumor selectivity of T cell engagers by logic-gated dual tumor-targeting.
Shen Y; Jin SJ; Chen YC; Liu WH; Li YM; Zhao WY; Xu YC; Chen SQ; Zhao WB
Pharmacol Res; 2023 Jun; 192():106781. PubMed ID: 37119880
[TBL] [Abstract][Full Text] [Related]
6. T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities.
Baeuerle PA; Wesche H
Curr Opin Oncol; 2022 Sep; 34(5):552-558. PubMed ID: 35880455
[TBL] [Abstract][Full Text] [Related]
7. Tumor-targeted superantigens produce curative tumor immunity with induction of memory and demonstrated antigen spreading.
Azulay M; Shahar M; Shany E; Elbaz E; Lifshits S; Törngren M; Friedmann A; Kramer R; Hedlund G
J Transl Med; 2023 Mar; 21(1):222. PubMed ID: 36967382
[TBL] [Abstract][Full Text] [Related]
8. Novel SPEA Superantigen Peptide Agonists and Peptide Agonist-TGFαL3 Conjugate. In Vitro Study of Their Growth-Inhibitory Effects for Targeted Cancer Immunotherapy.
Bashraheel SS; Goda SK
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445686
[TBL] [Abstract][Full Text] [Related]
9. Regression of EGFR positive established solid tumors in mice with the conditionally active T cell engager TAK-186.
Dettling DE; Kwok E; Quach L; Datt A; Degenhardt JD; Panchal A; Seto P; Krakow JL; Wall R; Hillier BJ; Zhu Y; Vinogradova M; DuBridge RB; May C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35728872
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer.
Wang Q; Yu H; Zhang L; Ju D; Pan J; Xia D; Yao H; Zhang W; Wang J; Cao X
J Mol Med (Berl); 2002 Sep; 80(9):585-94. PubMed ID: 12226740
[TBL] [Abstract][Full Text] [Related]
11. Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity.
Forsberg G; Skartved NJ; Wallén-Ohman M; Nyhlén HC; Behm K; Hedlund G; Nederman T
J Immunother; 2010 Jun; 33(5):492-9. PubMed ID: 20463598
[TBL] [Abstract][Full Text] [Related]
12. Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma.
Yoneyama T; Kim MS; Piatkov K; Wang H; Zhu AZX
PLoS Comput Biol; 2022 Jul; 18(7):e1009715. PubMed ID: 35839267
[TBL] [Abstract][Full Text] [Related]
13. Camelid-derived Tcell engagers harnessing human γδ T cells as promising antitumor immunotherapeutic agents.
Boutin L; Barjon C; Chauvet M; Lafrance L; Senechal E; Bourges D; Vigne E; Scotet E
Eur J Immunol; 2024 May; ():e2350773. PubMed ID: 38804118
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model.
Ma H; Wang H; Sové RJ; Wang J; Giragossian C; Popel AS
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32859743
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.
Crupi MJF; Taha Z; Janssen TJA; Petryk J; Boulton S; Alluqmani N; Jirovec A; Kassas O; Khan ST; Vallati S; Lee E; Huang BZ; Huh M; Pikor L; He X; Marius R; Austin B; Duong J; Pelin A; Neault S; Azad T; Breitbach CJ; Stojdl DF; Burgess MF; McComb S; Auer R; Diallo JS; Ilkow CS; Bell JC
Front Immunol; 2022; 13():1029269. PubMed ID: 36405739
[TBL] [Abstract][Full Text] [Related]
16. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
Inoue M; Plautz GE; Shu S
Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
[TBL] [Abstract][Full Text] [Related]
17. Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model.
Zorn JA; Wheeler ML; Barnes RM; Kaberna J; Morishige W; Harris M; Huang RY; Lohre J; Chang YC; Chau B; Powers K; Schindler I; Neradugomma N; Thomas W; Liao X; Zhou Y; West SM; Wang F; Kotapati S; Chen G; Yamazoe S; Kosenko A; Dollinger G; Sproul T; Rajpal A; Strop P
Sci Rep; 2022 Mar; 12(1):3530. PubMed ID: 35241687
[TBL] [Abstract][Full Text] [Related]
18. A Quantitative Systems Pharmacology Model of T Cell Engager Applied to Solid Tumor.
Ma H; Wang H; Sove RJ; Jafarnejad M; Tsai CH; Wang J; Giragossian C; Popel AS
AAPS J; 2020 Jun; 22(4):85. PubMed ID: 32533270
[TBL] [Abstract][Full Text] [Related]
19. Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager.
Xiao X; Cheng Y; Zheng X; Fang Y; Zhang Y; Sun R; Tian Z; Sun H
Front Immunol; 2023; 14():1113303. PubMed ID: 37114050
[TBL] [Abstract][Full Text] [Related]
20. Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors.
Cattaruzza F; Nazeer A; To M; Hammond M; Koski C; Liu LY; Pete Yeung V; Rennerfeldt DA; Henkensiefken A; Fox M; Lam S; Morrissey KM; Lange Z; Podust VN; Derynck MK; Irving BA; Schellenberger V
Nat Cancer; 2023 Apr; 4(4):485-501. PubMed ID: 36997747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
